

Femarelle®

Recharge

INTENDED USE:

Femarelle® Recharge is intended for women during menopause for the management of symptoms derived from the de-regulation of hormonal activity due to the decline of estrogen levels following menopause.

WHY IS FEMARELLE® RECHARGE RIGHT FOR YOU?

Studies have shown that relief of menopausal symptoms and a sense of overall well-being are usually felt within the first month of use. Three in four women report relief of their bothersome symptoms.

These results were achieved without leading to any negative changes within the body; no changes were seen in endometrial thickness or in the uterus and no changes occurred on the breast tissue and on blood clotting time. (For full list of published studies please see reverse page)

Femarelle® Recharge is endorsed & recommended by leading experts worldwide.

WHAT IS FEMARELLE® RECHARGE?

Femarelle® Recharge comprises a unique formulation that includes the proprietary fermented soy derivative (DT56a), flaxseed and vitamin B6, which contributes to the regulation of hormonal activity, reduction of tiredness and fatigue, normal functioning of the nervous system, normal psychological function and normal energy-yielding metabolism.

Femarelle® Recharge is produced by employing a unique manufacturing procedure without using any harsh chemicals during the production process. The proprietary soy extract of DT56a uses the whole soy compound. This unique method increases the bio-availability of the active components that are found in Femarelle® Recharge. Furthermore, the manufacturing process is subject to rigorous and comprehensive testing so that you will be able to receive the same product with the same efficacy and safety as seen in the numerous published studies.

Femarelle® Recharge contains no estrogen and is not an isoflavone isolate.

WHAT IS MENOPAUSE?

When a woman reaches her early forties, there are fewer ovarian follicles left in the ovaries. As a result, ovulation occurs less frequently. Because the follicles produce much of the estrogen in the body, estrogen levels also begin to decline. Estrogen levels eventually decrease to the point where buildup of the uterus lining no longer occurs, resulting in cessation of menstruation

and onset of menopause.

The majority of women experience natural menopause between the ages of 45 and 55. However, menopause can occur as early as in a woman's 30's and as late as in her 60's. Menopause is a natural event, not a disease. Hot flushes, night sweats, sleep disturbance, fatigue are only a few of the symptoms that are associated with the decline in estrogen levels following menopause, although symptoms vary from woman to woman, the overall feeling is of a decline in the quality of life.

RECOMMENDED INTAKE:

Femarelle® Recharge should be taken twice a day, one capsule in the morning and one in the evening. Swallow the capsule with some water. Femarelle® Recharge can be taken with or without food. It is important that you take two capsules a day as this is the required dose for optimal benefit.

If a dose is missed, one capsule should be taken as soon as possible and the regular schedule should then be continued. There is no need to take a double dose to make up for a missed dose.

INTENDED USE:

Femarelle® Recharge is a food supplement Intended for women during menopause for the management of symptoms derived from the de-regulation of hormonal activity due to the decline of estrogen levels following menopause.

COMPOSITION:

Each capsule contains:

DT56a- Glycine max (Fermented SOYBEAN extract)	322 mg
Linum usitatissimum (Ground roasted flaxseed)	108 mg
Capsule (Bovine gelatin- BSE/ TSE free)	96 mg
Vitamin B ₆ (Pyridoxine Hydrochloride)	1 mg

CAUTION:

Please note that supplements should not be used as a substitute for a varied diet and healthy lifestyle. As with other supplements, if you have any condition requiring medical attention or are taking prescribed drugs, consult your doctor before taking this product. Not for use during pregnancy, breastfeeding or for children under 12.

Femarelle®

Recharge

ADVERSE REACTIONS:

No significant adverse reactions have been reported to date. However, along with its desired effects, any product may have some unwanted effects, these effects were found to be transient and disappeared once the product was discontinued. Your healthcare practitioner should be informed as soon as possible in case you feel unwell while using this product. Any adverse events should also be reported to:
pharmacovigilancemt@mint.com.mt

STORAGE:

Store in a cool and dry place (room temperature- do not exceed 30°C). Even if kept in their original container and stored as recommended, health products may be kept for a limited period. Please note that you can't use it beyond the expiry date written on the blister pack. Do not store different medications in the same package. Keep out of reach of children.

MANUFACTURER:

Se-cure Pharmaceuticals Ltd., Dalton Industrial Area, 1381100, Israel

DISTRIBUTOR:

Mint Health Ltd, 3 / 4, Cantrija Complex, Triq it-Targa, Il-Maghtab, Naxxar NXR6613, MALTA

For more information or questions, please visit our website at www.femarelle.mt

References:

1. Yoles I. et al. Efficacy and Safety of Standard versus Low Dose of Femarelle (Tofupill) for the Treatment of Menopausal Symptoms. *J. of Clin Exper Obstet Gynecol* 2004; 31(2):123-26.
2. Labos G., Trakakis E. et al Efficacy and safety of DT56a (Femarelle) compared to hormone therapy in Greek postmenopausal women. *J Endocrinol. Invest.* 2013; 36(7):521-6
3. Genazzani AR et al. Brain region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats. *Menopause* 2009; 16(5):1037-43.
4. Genazzani A., Nachtigall L., Panay N. & Yoles I. Symposium: 2 Continents, 3 cultures, 4 countries, 2,000 women and Femarelle®; *13th World Congress on Menopause*. Rome, Italy June 2011
5. Nachtigall M. et al. A Prospective Study of DT56a (Femarelle) for the Treatment of Postmenopausal Vaginal Atrophy. *Menopause* book of abstract of the NAMS 22nd Annual Meeting, Sept, 2011, p. 55
6. Yoles I. et al. Tofupill/Femarelle (DT56a) - a New Phyto-Selective Estrogen Receptor Modulator-like Substance for the Treatment of Postmenopausal Bone Loss. *Menopause* 2003; 10(6):522-25
7. Somjen D, Yoles I. DT56a (Tofupill/Femarelle), selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. *J. of Steroid Biochemistry & Molecular Biology* 2003; 86(1):93-98
8. Somjen D. et al. DT56a (Femarelle/Tofupill) Stimulates Bone Formation in Female Rats. *British J. of Obstetrics & Gynecology* 2005; 112(7):981-85.
9. Somjen D., Katzburg S. Lieberherr M., Hendel D., Yoles I. DT56a Stimulates Gender-Specific Human Cultured Bone Cells In Vitro. *J. of Steroid Biochemistry & Molecular Biology* 2006; 98(1):90-96.
10. Somjen D. et al. The Effects of Native and Synthetic Estrogenic Compounds as well as Vitamin D Less-Calcemic Analogs on Adipocytes Content in Rat Bone Marrow. *J Endocrinol Invest.* 2011;34(2):106-10
11. Yoles I., and Lilling G. Pharmacological Doses of the Natural phyto-SERM DT56a (Femarelle) Have no Effect on MCF-7 Breast Cancer Cell-Line. *European J. of Obstetrics & Gynecology & Reproductive Biology* 2006; 130(1):140-141.
12. Nachtigall M et al. The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women. *Menopause* 2011;18,(3):285-288
13. Oropeza M.V, Orozco S, Ponce H, Campos M.G. Tofupill lacks peripheral estrogen-like actions in the rat reproductive tract. *Reproductive Toxicology* 2005; 20(2):261-66.
14. Somjen D, Yoles I. DT56a (Femarelle): a Natural Selective Estrogen Receptor Modulator (SERM). *J. of Steroid Biochemistry & Molecular Biology* 2007; 104:252-58.
15. Somjen D. et al. DT56a (Femarelle); contrary to estradiol-17β; is effective in human derived female osteoblasts in hyperglycemic condition. *J Steroid Biochem Mol Biol.* 2011; 123:25-29
16. Sánchez-Borrego R, Mendoza N, Llana P. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms; *Climacteric.* 2015;18(6):813-6
17. Sánchez-Borrego R et al. Efficacy and safety of a phyto-SERM as an alternative to hormone therapy; *Climacteric.* 2015 Jun;18(3):350-7
18. Somjen D. et al. Interaction between the effects of the selective estrogen modulator Femarelle and a vitamin D analog in human umbilical artery vascular smooth muscle cells. *J Steroid Biochem Mol Biol.* 2017 May 20 [Epub ahead of print]

In order to view the articles please insert Femarelle when entering pubmed: <http://www.ncbi.nlm.nih.gov/pubmed/>

We invite you to share your experience of Femarelle® Recharge. Please send an e-mail to: info@se-curepharma.com or join us on Facebook.

We, at Se-cure Pharmaceuticals Ltd, are constantly investing in bringing you as much information regarding the benefits that Femarelle® Recharge can provide you.

You can follow us on: 